### Emcure

To,

Dear Sir/Madam,

# Subject: Disclosure of Key Performance Indicators (KPIs) under the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018

Pursuant to the provisions of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, please find enclosed the Key Performance Indicators (KPIs) for Financial year ended March 31, 2025 (*in comparison with the previous two financial years*) as **Annexure-A**.

The same has been certified by M/s. R.B. Sharma and Co., Chartered Accountants (ICAI Firm Registration No.: 109971W).

You are requested to take the above information on your records.

Thanking you,

For Emcure Pharmaceuticals Limited

Chetan Sharma Company Secretary & Compliance Officer Membership Number: F8352

Annexure – A
Key Performance Indicators (KPIs)

Sr. No.	KPI*	Explanation		
1.	Percentage of revenue from operations attributable to sales in India	Revenue from operations within India as percentage of revenue from operations provides information regarding the geographic mix of our business.		
2.	Percentage of revenue from operations attributable to sales outside India	Revenue from operations outside India as percentage of revenue from operations provides information regarding the geographic mix of our business.		
3.	EBITDA	EBITDA is an indicator of the operational profitability and financial performance of our business.		
4.	EBITDA Margin	EBITDA margin provides the financial benchmarking against peers as well as to compare against the historical performance of our business.		
5.	РАТ	PAT provides information regarding the overall profitability of our business.		
6.	PAT Margin	PAT margin is an indicator of the overall profitability of our business and provides the financial benchmarking against peer as well as to compare against the historical performance of our business.		
7.	Return on Capital Employed (RoCE)	ROCE provides how efficiently our Company generates earnings from the capital employed in our business.		

\*The KPIs disclosed herein have been approved by the Audit Committee at its meeting held on June 21, 2025. There is no change in KPI's post listing of the Company.

## Details of KPIs as at and for the Financial Years ended March 31, 2025, March 31, 2024 and March 31, 2023:

(₹ in million, unless mentioned other			
КРІ	Fiscal 2025	Fiscal 2024	Fiscal 2023
Percentage of revenue from operations attributable to sales in India (in %)	46.34	48.28	53.16
Percentage of revenue from operations attributable to sales outside India (in %)	53.65	51.72	46.84
EBITDA <sup>(1)</sup>	15,312.61	12,767.82	12,209.41
EBITDA Margin (in %) <sup>(2)</sup>	19.23	19.01	20.24
PAT <sup>(3)</sup>	7,074.67	5,275.75	5,618.45
PAT Margin (in %) <sup>(4)</sup>	8.88	7.86	9.31
RoCE (in %) <sup>(5)</sup>	22.04	19.37	22.01

### **Emcure Pharmaceuticals Limited**

Registered Office: Plot No. P-1 & P-2, IT-BT Park, Phase-II, M.I.D.C., Hinjawadi, Pune - 411057, Maharashtra, India Phone Nos.: +91 20 – 35070033/ 35070000 Fax No.: +91 20 3507 0060 E-mail: corporate@emcure.com Website: www.emcure.com CIN: L24231PN1981PLC024251

## Emcure

#### Notes:

- 1 EBITDA is defined as earnings before interest, taxes, depreciation, and amortization.
- 2 EBITDA Margin is defined as our EBITDA during a given period as a percentage of total income during that period.
- 3 PAT is defined as Profit for the year.
- 4 PAT Margin refers to profit after tax margin, is calculated by dividing our profit for a given year by total income for that year and is expressed as a percentage.
- 5 RoCE is calculated by dividing our EBIT for a given period by Capital Employed (i.e., total equity plus net debt) as of the end of that period.

Emcure Pharmaceuticals Limited Registered Office: Plot No. P-1 & P-2, IT-BT Park, Phase-II, M.I.D.C., Hinjawadi, Pune - 411057, Maharashtra, India Phone Nos.: +91 20 – 35070033/ 35070000 Fax No.: +91 20 3507 0060 E-mail: corporate@emcure.com Website: www.emcure.com CIN: L24231PN1981PLC024251